Portfolio Company Headlines

November 21, 2019

Austin, TX
Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

November 18, 2019

Boston, MA and Austin, TX
Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

September 30, 2019

Austin, TX and Ames, IA
NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases

July 10, 2019

Plymouth Meeting, PA
Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology

June 26, 2019

Austin, TX
Remedy Raises $10 Million to Bring Quality Care Closer to Patients

June 17, 2019

Austin, TX
Molecular Templates Announces FDA Acceptance of IND Application for TAK-169, An Engineered Toxin Body Targeting CD38

May 16, 2019

Menlo Park, CA
FARAPULSE featured prominently at 2019 HRS Scientific Sessions

May 8, 2019

Menlo Park, CA
FARAPULSE Receives FDA Breakthrough Designation for its Endocardial Pulsed Field Ablation System

May 3, 2019

Austin, TX
BioStable Science & Engineering Surpasses 500 Patients Treated Worldwide with the HAART Devices

April 23, 2019

San Carlos, CA
BAROnova Announces FDA Approval of the TransPyloric Shuttle® (TPS®) Device

February 21, 2019

Plymouth Meeting, PA
Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies

December 27, 2018

Santa Rosa, CA
Boston Scientific Exercises Option to Acquire Millipede, Inc. for $540M (Santé Ventures Leads Deal as Only Institutional Investor)

December 5, 2018

Houston, TX
Iterion Therapeutics Initiates Phase I Clinical Study of Tegavivint in Patients with Desmoid Tumors

November 2, 2018

Austin, TX
HNI Healthcare Acquires Martin Healthcare Group to Expand Footprint

September 25, 2018

Austin, TX
Molecular Templates, Inc. Announces Closing of Public Offering of Common Stock and the Full Exercise of the Underwriters’ Option to Purchase Additional Shares